News
Public · Published
Goldman Sachs maintains Ultragenyx Pharmaceutical at Neutral, lowers price target to $17 from $19
Goldman Sachs kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target, an estimate of a possible future share price, to $17 from $19. The new target is 2.2% above the stock's November 3 closing price of $16.63.
Published:
Updated:
What happened
Goldman Sachs kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target, an estimate of a possible future share price, to $17 from $19. The new target is 2.2% above the stock’s November 3 closing price of $16.63.
Confirmed
Global impact / market context
The lower target signals that Goldman Sachs sees less potential share-price appreciation than before, while its Neutral rating remains unchanged. If investors give weight to that assessment, it could temper buying interest; the article reports no actual market reaction or change to the company’s business.
Analyst inference
Recent analyst views in the article span targets of $16 to $22, with Wells Fargo at $19 and Wedbush at $22, both maintaining their ratings. Goldman’s $17 target sits within that range, so the update is a modest reset rather than an outlier forecast.
Confirmed
What to watch
- Check whether Ultragenyx’s share price moves toward or away from Goldman’s $17 target; the article gives a November 3 close but no subsequent trading response. Analyst inference
- Compare future analyst targets with the reported $16–$22 range to see whether views converge or diverge; the supplied article lists only three recent notes. Analyst inference
- Watch for further analyst rating or target changes, since the article reports Goldman’s cut alongside recent Neutral or Equal-Weight views from other firms. Analyst inference
Evidence
- Original source link unavailable